Several U.S. states and municipalities have begun restricting or eliminating Medicaid coverage for GLP-1 weight-loss medications such as Ozempic and Wegovy, citing rising costs as demand for these drugs has increased dramatically in recent years.

The coverage reductions affect low-income residents and public employees who previously had access to these medications through government-funded health programs. Health experts warn that short-term financial savings from eliminating coverage may be offset by long-term costs associated with obesity-related health complications.

Separately, federal health programs are facing potential changes under the current administration's domestic policy proposals. New York state officials are developing contingency plans to maintain insurance coverage for residents in response to proposed federal regulations that could affect Medicaid programs.

The Trump administration has also announced changes to the Title X federal reproductive health program, which provides services to approximately 2 million low-income Americans. Program administrators at the Department of Health and Human Services have issued new guidance to partner clinics and medical practices, indicating a shift in the program's focus from contraception services toward what officials describe as pro-conception initiatives.

The administration's proposed budget eliminates funding for Title X entirely, marking a significant change to a program that has operated for decades as a contraception-focused initiative. These modifications come as various federal health programs undergo policy reviews that could affect millions of Americans' access to healthcare services.